Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK up-regulation

Cardiovascular Research

Volumn 89, Issue 2, 2011, Pages 309-319

  Konishi, Masanori ^a   Haraguchi, Go ^a   Ohigashi, Hirokazu ^a   Ishihara, Takashi ^a   Saito, Kiyomi ^b   Nakano, Yasuko ^b   Isobe, Mitsuaki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b SHOWA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cardiomyopathy; Heart failure

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; BIOLOGICAL MARKER; CASPASE 3; COMPLEMENTARY DNA; CYTOCHROME C; DORSOMORPHIN; DOXORUBICIN; ENZYME INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD PRESSURE; C57BL 6 MOUSE; CARDIOMYOPATHY; CELL VIABILITY; CONTROLLED STUDY; DRUG INDUCED DISEASE; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HEART CELL CULTURE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART RATE; MITOCHONDRION; MOUSE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SURVIVAL RATE; TRANSGENIC MOUSE; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADIPONECTIN; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARDIOMYOPATHIES; CELLS, CULTURED; DOXORUBICIN; FIBROSIS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOCHONDRIA, HEART; MYOCARDIUM; MYOCYTES, CARDIAC; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZOLES; PYRIMIDINES; RECEPTORS, ADIPONECTIN; TIME FACTORS; UP-REGULATION;

EID: 78751554136     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq335     Document Type: Article

References (34)

1. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
2. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T et al. Structure- function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 2003;278:9073-9085.
3. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423: 762-769.
4. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-1599.
5. George J, Patal S,Wexler D, Sharabi Y, Peleg E, Kamari Y et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart 2006;92:1420-1424.
6. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756-1762.
7. Mosterd A, Cost B, Hoes AW, de Bruijne MC, Deckers JW, Hofman A et al. The prognosis of heart failure in the general population: the Rotterdam Study. Eur Heart J 2001;22:1318-1327.
8. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730-1737.
9. Kojima S, Funahashi T, Otsuka F, Maruyoshi H, Yamashita T, Kajiwara I et al. Future adverse cardiac events can be predicted by persistently low plasma adiponectin concentrations in men and marked reductions of adiponectin in women after acute myocardial infarction. Atherosclerosis 2007;194:204-213.
10. Hong SJ, Park CG, Seo HS, Oh DJ, Ro YM. Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press 2004;13:236-242.
11. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8:731-737.
12. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 2007;115:1408-1416.
13. Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR et al. Adiponectinmediated modulation of hypertrophic signals in the heart. Nat Med 2004;10: 1384-1389.
14. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2- dependent mechanisms. Nat Med 2005;11:1096-1103.
15. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339: 900-905.
16. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007;49:330-352.
17. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000;22:263-302.
18. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem 2000;207:77-86.
19. Neilan TG, Blake SL, Ichinose F, Raher MJ, Buys ES, Jassal DS et al. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation 2007;116:506-514.
20. Maejima Y, Adachi S, Morikawa K, Ito H, Isobe M. Nitric oxide inhibits myocardial apoptosis by preventing caspase-3 activity via S-nitrosylation. J Mol Cell Cardiol 2005;38:163-174.
21. Tokarska-Schlattner M, Zaugg M, da Silva R, Lucchinetti E, Schaub MC, Wallimann T et al. Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. Am J Physiol Heart Circ Physiol 2005;289:H37-H47.
22. Saito K, Arata S, Hosono T, Sano Y, Takahashi K, Choi-Miura NH et al. Adiponectin plays an important role in efficient energy usage under energy shortage. Biochim Biophys Acta 2006;1761:709-716.
23. Delgado RM 3rd, Nawar MA, Zewail AM, Kar B, Vaughn WK, Wu KK et al. Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure. Circulation 2004;109: 1428-1433.
24. Nobori K, Ito H, Tamamori-Adachi M, Adachi S, Ono Y, Kawauchi J et al. ATF3 inhibits doxorubicin-induced apoptosis in cardiac myocytes: a novel cardioprotective role of ATF3. J Mol Cell Cardiol 2002;34:1387-1397.
25. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 2008;4:33-41.
26. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-1295.
27. Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem Sci 2004;29:18-24. (Pubitemid 38068476)
28. Hardie DG. AMP-activated protein kinase: the guardian of cardiac energy status. J Clin Invest 2004;114:465-468.
29. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26: 439-451.
30. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281:1309-1312.
31. Sabbah HN. Apoptotic cell death in heart failure. Cardiovasc Res 2000;45:704-712.
32. Chen X, Chen Y, Bi Y, Fu N, Shan C, Wang S et al. Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy. Cardiovasc Drugs Ther 2007;21:367-374.
33. Rogers CQ, Ajmo JM, You M. Adiponectin and alcoholic fatty liver disease. IUBMB Life 2008;60:790-797.
34. Saito Y, Fujioka D, Kawabata K, Kobayashi T, Yano T, Nakamura T et al. Statin reverses reduction of adiponectin receptor expression in infarcted heart and in TNF-alpha-treated cardiomyocytes in association with improved glucose uptake. Am J Physiol Heart Circ Physiol 2007;293:H3490-H3497.